Testing Tumor Biopsies to Predict Response to Immunotherapy in Cancer
Collects tumor tissue from adults with cancer during routine biopsies.
Plain-language title generated from the registry record
Registry title: Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Key facts
- Where
- Fort Smith, Forth Worth, Frederick, Oklahoma City, Springfield, St Louis, and Temple, United StatesSee the 8 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a suspected or confirmed cancer who are having a biopsy to get tumor tissue as part of their normal care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Suspected or confirmed cancer that will be checked by a biopsy.
- Earlier treatment
- People newly diagnosed or with suspected cancer must not have had any treatment before the biopsy. All others must have the biopsy before starting their next line of treatment.
Main reasons for not taking part
- Known auto-immune disease or a prior condition that rules out immunotherapy (IO) treatment
- Prior organ transplant, chronic kidney disease or chronic liver disease that rules out immunotherapy
- Severely weakened immune system, for example on immunosuppressants, HIV positive on antiretrovirals, or after a transplant
- Pregnancy
Read by machine on 9 November 2026.
Where in United States
- Mercy Hospital - FTSFort Smith, United StatesTaking people
- JPS Health NetworkForth Worth, United StatesTaking people
- Frederick Health HospitalFrederick, United StatesTaking people
- Mercy Hospital - OKCOklahoma City, United StatesTaking people
- Mercy Hospital - SPGSpringfield, United StatesTaking people
- Mercy Hospital -STLSt Louis, United StatesTaking people
- Mercy Hospital SouthSt Louis, United StatesTaking people
- Baylor Scott and White BiorepositoryTemple, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Elephas
- Trial code
- NCT07327489
- Record updated
- 29 June 2026
- Original description
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.Read full original descriptionShow less
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
Inclusion: Able and willing to provide informed consent for participation; Age ≥18 years at time of consent; Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy; Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.
Exclusion: Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment; Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients; Pregnant person(s).